Summary
Immunotherapy with recombinant interleukin-2 (rIL-2) and lymphokine-activated killer cells (LAK) has become a new form of therapy that has been shown to induce remissions in patients with renal cell carcinoma and melanoma. Despite encouraging results, this form of therapy has been associated with increasing toxicity, often requiring therapy in an intensive-care unit. In this report severe intrahepatic cholestasis occurred in two patients receiving rIL-2 and LAK cells. This form of cholestasis appeared to be directly related to rIL-2 administration at a doses of 2×106 U/m2 and 3x106 U/m2 t.i.d. A liver biopsy showed moderate hepatocellular bile stasis, with lobular and portal inflamation. All other studies for potential cause of this cholestasis were negative, including studies for metastatic disease. When therapy was discontinued, evidence for cholestasis and bile stasis resolved. We conclude that rIL-2 is a drug with a potential to induce severe hepatic injury that is reversible upon cessation of therapy with rIL-2. Further care should be exercised when rIL-2 is administered to patients with abnormal liver function.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Atkins MB, Gould JA, Allegretta M et al. (1986) Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J Clin Oncol 4:1380–1391
Hsieh KH, Shu S, Lee CS, Chu CT, Yang CS, Chang KJ (1987) Lysis of primary hepatic tumors by lymphokine activated killer cells. Gut 28:117–124
Ikawa M, Yoneyama M, Nako T, Hiraya K (1978) Subacute toxicity of detergents: effect of detergents on liver and kidney enzymes in rats. Tokyo-toritsu Kenky, Nempo ISS (Tokyo Prefectural Institute, Annual Report ISS) vol 29 (1), pp 5863–5865
Lotze MT, Robb Rj, Sharrow SO, Frana LW, Rosenberg SA (1984) Systemic administration of interleukin-2 in humans. J Biol Response Mod 3:475–482
Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer M, Rosenberg SA (1985a) In vivo administration of purified human interleukin-2. I. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 135:2865–2875
Lotze MT, Fana LW, Sharrow SO, Robb RJ, Rosenberg SA (1985b) In vivo administration of purified human interleukin-2. I. Halflife and immunologic effects of the jurkat cell line-derived interleukin-2. J Immunol 134:157–166
Lotze MT, Chang AE, Seipp CA, Simson C, Vetto JT, Rosenberg SA (1986a) High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity, and histologic findings. JAMA 256:3117–3124
Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Seipp CA, Rosenberg SA (1986b) Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58:2764–2772
Matory YL, Chang AE, Lipford EH, Braziel R, Hyatt CL, McDonald HD, Rosenberg SA (1985) Toxicity of recombinant human interleukin-2 in rats following intravenous infusion. J Biol Response Mod 4:377–390
Raven H, Schriener H, Kopp O, Peters O (1973) Biochemical environment problems. I. Liver injury by surfactant dodecyl sulphate. Arzneimittelforschung 23:134–139
Rosenberg SA, Lotze MT, Muul LM et al. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492
Rosenberg SA, Lotze MT, Muul LM et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897
Sohn R, Marinetti G (1974) Effect of detergents on the enzyme activities of the rat liver plasma membrane. Chem Phys Lipids 12:730
West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898–905
Zimmerman HJ (1978) Hepatotoxicity. Appleton-Century Crofts, New York, pp 91–121
Author information
Authors and Affiliations
Additional information
Supported in part by Dr. I. Fund Foundation, Hoffmann-La Roche Inc., Nutley, New Jersey, and the Sarah C. Upham Trust
Rights and permissions
About this article
Cite this article
Hoffman, M., Mittelman, A., Dworkin, B. et al. Severe intrahepatic cholestasis in patients treated with recombinant interleukin-2 and lymphokine-activated killer cells. J Cancer Res Clin Oncol 115, 175–178 (1989). https://doi.org/10.1007/BF00397920
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00397920